Pharma AI Tracker

Sobi's first-quarter 2026 report says the company kicked off a learning journey for all employees aimed at accelerating smart and responsible use of digital tools, including AI, and that new learning resources and a shared learning channel were launched during the campaign week.

Moderna picked Salesforce's Agentforce Life Sciences for Customer Engagement to bring its global commercial operations onto one platform.

Partners: Salesforce

J&J's CIO cited AI helping manufacturing teams decide the right time and temperature to add solvent during production.

J&J's CIO said AI now handles much of the preparation of clinical trial reports for regulators, cutting a job that took hundreds of hours to minutes.

J&J uses AI to screen chemical and biologic candidates and says this has halved lead optimization time and sped up two compounds.

Merck signed a multi-year deal with Google Cloud, worth up to about $1 billion, to roll out an agentic AI platform across R&D, manufacturing, commercial and corporate teams.

Partners: Google Cloud

At ISHLT 2026, United Therapeutics listed a presentation from its ex-vivo lung perfusion program on using machine learning for earlier, real-time predictions of whether a lung will be accepted for transplant during rc-EVLP.

BeOne's 2025 sustainability report says the company set budgetary targets to advance non-animal research tools through its in-house computational drug design and AI drug discovery groups. It says those groups now play an active role in every BeOne research program.

BeOne says it leverages assistive AI and digital tools to analyze safety data more efficiently and to speed the identification of potential risks. The statement sits in the report's description of its in-house global patient-safety and pharmacovigilance work.

A partnership to apply OpenAI's models from drug discovery to commercial operations and to upskill Novo's workforce.

Partners: OpenAI

Tempus announced an expanded collaboration giving Gilead enterprise-wide access to Tempus's AI-driven Lens platform and multimodal data for oncology R&D and real-world evidence.

Partners: Tempus AI

Insmed's 2025 annual report says that in early 2025 the company launched InQuiry, its proprietary generative AI assistant, which uses internal data to summarize documents, create content and produce meeting recaps. The report says InQuiry fully integrates across Insmed and is helping improve workflows, and that teams have realized productivity gains on tasks such as job descriptions, development plans and templates.

Insmed says it is leveraging AI for labor-intensive tasks that include determining next best actions for case managers on its Patient Services team, along with translating documents and producing HEOR dossiers. The same sentence says the company is exploring how AI may be used to write first drafts of IND applications and to assess business-development opportunities.

A generative AI chatbot built on Dataiku that answers field sales questions about incentive-compensation rules.

Partners: Dataiku

A Dataiku-built generative AI tool that assesses scientific literature for relevance and gaps for medical affairs.

Partners: Dataiku

At its March 31, 2026 R&D Day, Astellas said NVIDIA's AI-powered supercomputing for small-molecule drug design has already been implemented.

In the same R&D Day remarks, Astellas said it is introducing an AI-enabled protein station for research automation, as part of aiming to accelerate development of biopharmaceuticals and improve productivity.

In the same remarks, Astellas said gene therapy guided by AI will lead to precise organ targeting, reduced toxicity and enhanced treatment.

Astellas said that using Evinova's AI-native Study Designer will enable it to design more sophisticated, patient-centered clinical trials efficiently. In the question session, the R&D head described that study designer as a platform on which AI agents discuss protocol design.

Partners: Evinova

In the same R&D Day question session, Astellas said each team is already using AI to generate clinical study reports. The same answer says AI translation has sped translation of clinical-trial documents, with human confirmation still required.

BeOne says it recently convened a Patient Advocacy AI Innovation Lab with members of the blood-cancer community to discuss patient and caregiver needs, how to harness the technology, and how to guide patients in using AI tools. The same article says BeOne is using those insights to develop new digital tools to help patients, including people living with chronic lymphocytic leukemia, navigate their care.

Shionogi says the Artificial Intelligence Statistical Programming System, released in September 2023, enables AI to automatically generate the SAS statistical analysis programs required for clinical trials and achieved a 30% reduction in standard work hours.

Shionogi says the Generative AI Group, established in October 2024, is advancing the development, implementation and internal deployment of operational support systems that use generative AI. The same page says the company aims to use generative AI large language models for efficiency and quality in medical writing, including protocols and clinical study reports.

Hengrui's 2025 annual report says the company vigorously develops AI-driven drug discovery, which it abbreviates AIDD, and that AI technology is deeply integrated throughout its R&D pipeline.

Innovent's 2025 reporting says the company kept pushing an intelligent upgrade of its R&D system, and sped up the deep integration of artificial intelligence technologies across the whole drug development chain.